跳至主要内容
临床试验/NL-OMON49246
NL-OMON49246招募中3 期

Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial. - IVIG in myositis: TIME IS MUSCLE

Academisch Medisch Centrum0 个研究点目标入组 48 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
48

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Adult patients (18-80 years) with idiopathic inflammatory myopathy (IIM),
  • according to diagnostic criteria:
  • - Dermatomyositis
  • - Non-specific/overlap myositis including antisynthetase syndrome; formerly
  • known as polymyositis
  • - Immune mediated necrotizing myopathy
  • Disease duration; 12 months
  • Signed informed consent

排除标准

  • Disease duration > 12 months
  • Immunosuppressive medication within the last 12 months (azathioprine,
  • methotrexate plasmapheresis, IVIg, biologicals). We will allow prednisone dosed
  • as follows:
  • - Daily dose 20 mg or lower, used for two weeks or less
  • - Daily dose higher than 20 mg, used for 1 week or less
  • - No evident clinical response
  • Related to IVIG:
  • - History of thrombotic episodes within 10 years prior to enrolment
  • - Known allergic reactions or other severe reactions to any blood-derived
  • - Known IgA deficiency and IgA serum antibodies
  • - Pregnancy (wish)
  • Conditions that are likely to interfere with:
  • - Compliance (legal incompetent and/or incapacitated patients are excluded),
  • - Evaluation of efficacy (e.g. due to severe pre-existing disability as a
  • result of any other disease than myositis or due to language barrier)

研究者

相似试验